Status:
COMPLETED
Geriatric Anorexia Study 2.0
Lead Sponsor:
Boston University
Conditions:
Healthy
Frailty
Eligibility:
All Genders
65+ years
Brief Summary
Reduction in appetite and/or food intake among older individuals is referred to as anorexia of aging (AOA, also known as Geriatric Anorexia). AOA is linked with myriad comorbidities associated with ag...
Detailed Description
The overall aim of this study is to compare feasibility of body weight, body fat, body composition and activity assessments in elderly subjects in long-term care (LTC), nursing home, or assisted livin...
Eligibility Criteria
Inclusion
- \[separated into the three groups based on the Fried Criteria: 0 - robust, 1-2 - intermediate or pre-frail, 3 or above - frail; enrollment into individual frailty groups will close once the recruitment goal is reached for that group\]
- Male or female participants aged 65 years of age and over
- No recent hospitalizations/acute events in last 30 days
- No active or recent (within 12 months) cancer diagnosis except skin cancer \[limited to only non-complicated squamous and basal cell skin cancer (SCC/BCC)\]
- Body mass index (BMI) \< 30 kg/m2
- Able to understand and cooperate with study procedures and able to read, understand and provide informed consent. Evidence of a personally signed and dated informed consent document indicating that the participant, if necessary, their legally authorized representative (LAR) has been informed of all pertinent aspects of the study.
- Native English speakers or demonstrated fluency in English as determined by the Investigator
- WRAT-4 Word Reading Subtest equivalent to 8th grade reading level or greater
- Montreal Cognitive Assessment (MoCA) score of ≥ to 19
Exclusion
- Treatment with an investigational drug within 30 days of enrollment
- Moderate to severe alcohol use disorder diagnosis within 6 months of the screening as disclosed by the subject
- Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Boston University/Boston Medical Center (BU/BMC) employees directly involved in the conduct of the study
- Inability to comply with study requirements
- Life expectancy of less than 6 months, or actively enrolled in a palliative care program
- Has any clinically significant medical disorder, condition, disease, or clinically significant finding at screening that precludes subject's participation in study activities
- Participants with electronic implant such as pacemaker etc., due to Bioelectric Impedance Analysis (BIA) body composition devices (Tanita, Smart body scale) using tiny electrical signal for measurements
- At an increased risk of COVID-19 as determined by the Laboratory for Human Neurobiology COVID-19 Human Subject Risk Assessment Survey
- Temperature equal to or above 100.4 degrees F
- Modified Barthel Index of \<40
Key Trial Info
Start Date :
March 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 7 2022
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT05211973
Start Date
March 28 2022
End Date
September 7 2022
Last Update
September 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Evans Biomedical Research Center
Boston, Massachusetts, United States, 02118